Alcon launches new NSAID
Alcon has announced the launch of nepafenac ophthalmic suspension 0.3% (Ilevro), a new once-daily treatment option for pain and inflammation associated with cataract surgery.
Fort Worth, TX-Alcon has announced the launch of nepafenac ophthalmic suspension 0.3% (Ilevro), a new once-daily treatment option for pain and inflammation associated with cataract surgery.
In two double-masked, randomized clinical trials, the NSAID demonstrated superior clinical efficacy compared with its vehicle. Patients treated with product were less likely to have ocular pain and measurable signs of inflammation (cells and flare) at the end of treatment. Researchers found faster resolution of both inflammation and pain with the experimental medication.
“Effective management of pain and inflammation associated with cataract surgery is a priority for me,” said Stephen Lane, MD, adjunct clinical professor of ophthalmology, University of Minnesota, and medical director, Associated Eye Care, Minneapolis. “I am confident that this highly effective option, with its innovative formulation, will benefit my patients.”
For more articles in this issue of Ophthalmology Times eReport, click here.
